Following U.S. Stocks are among the “Most Active” Stocks in the course of recent trading session, Thursday: Coronado Biosciences Inc (NASDAQ:CNDO), Amicus Therapeutics, Inc (NASDAQ:FOLD), Regions Financial Corp (NYSE:RF), Freeport-McMoRan Inc (NYSE:FCX)

• Coronado Biosciences Inc (NASDAQ:CNDO), with shares skyrocketed 54.04% is now trading at $4.96, hitting new 52-week high of $5.35. The Stock is active as 15.96M shares changed hands versus its average volume of 456,394.00 shares.

• Amicus Therapeutics, Inc (NASDAQ:FOLD), with shares raised 30.05% is now trading at $12.16, hitting new 52-week high of $12.64. The Stock is active as 12.94M shares changed hands versus its average volume of 1.18M shares.

• Regions Financial Corp (NYSE:RF) with shares dipped -3.87% is now trading at $9.31. The Stock is active as 16.20M shares changed hands versus its average volume of 14.89M shares.

• Freeport-McMoRan Inc (NYSE:FCX) with shares declined -4.91% is now trading at $17.33. The Stock is active as 11.70M shares changed hands versus its average volume of 17.78M shares.

Latest NEWS regarding these Stocks are depicted underneath:

Coronado Biosciences, Inc. (NASDAQ:CNDO)

Today, Coronado Biosciences, Inc. (CNDO), declared the execution of an exclusive license contract with NeuPharma, Inc. to develop and commercialize novel irreversible, 3rd Generation EGFR inhibitors on a worldwide basis outside of certain Asian countries. The program is presently in pre-clinical development. Under the terms of the contract, Coronado will pay NeuPharma an up-front licensing fee in addition to make development and sales-based milestone payments and will pay a tiered single digit royalty on net sales.

NeuPharma is a biopharmaceutical corporation dedicated to research and development of innovative medicines for unmet medical needs. Through its proprietary drug discovery platform, NeuPharma is developing small molecule drugs for the treatment of cancers and neurodegenerative diseases.

Coronado Biosciences, Inc., a development stage biopharmaceutical corporation, develops novel immunotherapy agents for the treatment of autoimmune diseases and cancer.

Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Today, Amicus Therapeutics, Inc. (FOLD), a biopharmaceutical corporation at the forefront of therapies for rare and orphan diseases, declared that it has met very recently with regulatory authorities in Europe and the U.S. to talk about the approval pathways for the oral small molecule pharmacological chaperone migalastat HCl as a precision medicine monotherapy for Fabry patients who have amenable genetic mutations.

Meeting with European Rapporteurs:

The Corporation held a meeting with the assigned European Rapporteurs to talk about the forthcoming marketing authorization application (MAA) for migalastat monotherapy. Amicus Chief Medical Officer Dr. Jay Barth led the Amicus delegation at the meeting in Europe last week. It was the first face-to-face meeting with the assigned Rapporteurs on the projected dossier for migalastat monotherapy. The European Medicines Agency (EMA) assigns Rapporteurs to review the data in the MAA in detail and to provide guidance to sponsors during the regulatory approval process. The meeting was highly successful for Amicus. The key takeaways from the meeting comprise:

• Acknowledgment from the Rapporteurs of the continued noteworthy unmet need in Fabry disease, and the need for innovative treatment options such as migalastat monotherapy,
• The Rapporteurs commented favorably upon the quality and quantity of the migalastat data presented, which comprised of data from the two largest Phase 3 studies ever conducted in Fabry disease and over 400 patient years of data,
• The Rapporteurs also noted that the Amicus clinical development plan followed the preceding scientific guidance from EMA,
• The Rapporteurs agreed that Amicus may submit its MAA for migalastat monotherapy under the Full Approval pathway in the EU,
• The Rapporteurs indicated support for Amicus to request Accelerated Assessment1 in view of the migalastat data and the major public health interest that exists for Fabry patients.

Based on this feedback and other positive comments from the EU Regulatory officials, Amicus is accelerating the timing of the MAA submission for full approval for migalastat monotherapy from the middle of 2015 to the second quarter of 2015.

Amicus Therapeutics, Inc., a biopharmaceutical corporation, focuses on the discovery, development, and commercialization of medicines for various rare and orphan diseases. The Corporation is developing novel, first-in-class treatments for a broad range of human genetic diseases, with a focus on delivering new benefits to individuals with lysosomal storage diseases. Amicus’ lead programs in development comprise the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, in addition to next-generation enzyme replacement therapy (ERT) products for Fabry disease, Pompe disease, and MPS-1.

Regions Financial Corporation (NYSE:RF)

On Wednesday, Regions Financial Corporation (RF), has been recognized by Greenwich Associates for providing distinguished quality service to small business and middle market clients. Regions Bank received 28 Greenwich Excellence Awards in 2014, the highest number of awards received by any participating bank across the combined Small Business Banking and Middle Market Banking awards categories.

Greenwich Excellence Awards are based on feedback from more than 15,000 small businesses and nearly 13,000 middle market businesses that rate their bank in various categories, counting customer service, product capabilities, and likelihood to recommend.

Greenwich Associates is the leading research-based consulting firm servicing the financial services industry.

Regions Financial Corporation, together with its auxiliaries, provides banking and bank-related services to individual and corporate customers in the United States. Regions Financial Corporation (RF), with $120 billion in assets, is a member of the S&P 500 Index and is one of the nation’s largest full-service providers of consumer and commercial banking, wealth administration, mortgage, and insurance products and services.

Freeport-McMoRan Inc. (NYSE:FCX)

At its Grasberg mine in Papua, Freeport-McMoRan Inc. (FCX), closed down production.

According to Bloomberg, The corporation stopped production at the second-largest copper mine in the world by capacity as workers blocked an access road to the mine for a fourth day. Workers started blocking the access road to the complex on Monday to protest a settlement Freeport-McMoRan reached with other employees.

Freeport-McMoRan Inc., a natural resource corporation, engages in the attainment of mineral assets, and oil and natural gas resources. It primarily explores for copper, gold, molybdenum, cobalt, silver, and other metals, in addition to oil and gas.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.